Building an oncology powerhouse: Daiichi Sankyo's next phase of growth in Europe and Canada

▤ Summary

Daiichi Sankyo is expanding its oncology business in Europe and Canada after building a DXd antibody-drug conjugate platform. The company is positioning itself to commercialize a growing pipeline and strengthen its market presence. The piece frames this as the next phase of a longer-term strategy to build a full oncology powerhouse. This is a strategic company update for the life sciences sector rather than a product announcement or transaction.

▦ Linked Companies